Anti-Angiogenesis Drugs: Hopes and Disappointments in Certain Cancers
Pp. 97-107 (11)
Georgios M. Iatrakis
In cancer, neovascularization seems necessary for tumor progression and
metastasis. The hypothesis that cancer progression is angiogenesis-dependent has
repeatedly been confirmed by experimental inhibition of tumor growth with
angiogenesis inhibitors. Receptors for VEGF (VEGFRs) are expressed on tumor
endothelium and tumor cells and, as expected, VEGF-A overexpression is associated
with poor prognosis (reduced survival). There are both positive and negative
angiogenesis regulators and, as such, two strategies for inhibiting pathologic
angiogenesis can be adopted: the inhibition of positively-acting agents (e.g., VEGFR
inhibitors) and the administration of negatively-acting agents (e.g., angiostatin (from
the Greek words "angio" and "stasis" meaning stopping)).
Angiogenesis, Anti-angiogenesis drugs, Cancer, Growth factors,
Negative angiogenesis regulators, Positive angiogenesis regulators.
Technological Educational Institute of Athens, Αgiou Spyridonos, 12210 Egaleo, Athens, Greece.